Biochemical Markers for Preterm Labor and Birth: WHAT IS THEIR ROLE IN THE CARE OF PREGNANT WOMEN?

Abstract

Two biochemical tests, one for oncofetal fibronectin (fFN) and the other for estriol found in maternal saliva (SalEst) have been developed to improve the ability to predict preterm labor and birth. Fetal fibronectin is a protein secreted by the trophoblast and not normally present in vaginal and cervical secretions late in pregnancy. The presence of fFN between 22 and 37 weeks gestation may be a marker for preterm labor. Salivary estriol is a form of estrogen produced in the placenta from fetal precursors. Normally, estriol rises during pregnancy--the rise being accelerated 3 to 5 weeks prior to both term and preterm births. Both tests have high negative predictive values. This may serve to prevent unnecessary treatment of women with uterine contractions who are not truly in preterm labor. The fFN specimen is collected during vaginal examination. Sexual intercourse or vaginal examination within the prior 24 hours, vaginal bleeding, and uterine contractions may lead to a false positive test. Salivary estriol may be collected by the woman in her own home; however, specific instructions about eating, drinking, smoking, and the timing of saliva collection must be followed. Further study of both tests is required to determine their potential for reducing rates of preterm birth.